Cargando…
Efficacy Evaluation of Tissue Plasminogen Activator with Anti-Vascular Endothelial Growth Factor Drugs for Submacular Hemorrhage Treatment: A Meta-Analysis
Submacular hemorrhage (SMH) is the accumulation of blood in the macular area that can severely damage the macular structure and visual function. Recently, the intraocular administration of tissue plasminogen activator (TPA) with anti-vascular endothelial growth factor (anti-VEGF) drugs was reported...
Autores principales: | He, Xuejun, Cao, Wenye, Wang, Zhiyi, Zhang, Ningzhi, Xu, Kexin, Yu, Lu, Xing, Yiqiao, Yang, Ning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918283/ https://www.ncbi.nlm.nih.gov/pubmed/36769682 http://dx.doi.org/10.3390/jcm12031035 |
Ejemplares similares
-
Efficacy of Simultaneous Application of Subretinal Tissue Plasminogen Activator and Bevacizumab for Submacular Hemorrhages
por: Limon, Utku, et al.
Publicado: (2023) -
Tissue Plasminogen Activator Toxicity after Submacular Hemorrhage Repair
por: Islam, Yasmin, et al.
Publicado: (2021) -
Galectin-1-dependent ceRNA network in HRMECs revealed its association with retinal neovascularization
por: Yang, Ning, et al.
Publicado: (2023) -
Application Progress of High-Throughput Sequencing in Ocular Diseases
por: He, Xuejun, et al.
Publicado: (2022) -
Subretinal tissue plasminogen-assisted vitrectomy for posttraumatic full-thickness macular hole with submacular hemorrhage
por: Kumar, Pradeep, et al.
Publicado: (2018)